Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ameflu
- Development stage
- Unknown
- Lead developer
- OPV Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ameflu is a multi-symptom cold and flu medication developed and marketed by RV OPV Pharmaceuticals in Vietnam. It is a combination pharmaceutical product typically containing paracetamol (an analgesic and antipyretic), phenylephrine hydrochloride (a nasal decongestant), guaifenesin (an expectorant), and dextromethorphan hydrobromide (an antitussive). The drug is designed to provide comprehensive relief from symptoms associated with the common cold and influenza, including fever, minor aches and pains, nasal congestion, and cough. Various formulations exist under the Ameflu brand, such as Ameflu Night time, which includes the antihistamine chlorpheniramine maleate to aid sleep and reduce allergic symptoms, and Ameflu C, which combines paracetamol with ascorbic acid (Vitamin C).
- Brand names
- Ameflu
- Other names
- Ameflu Multi-Symptom ReliefAmeflu DayAmeflu NightAmeflu C
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADRA1A (α1A)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Ameflu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ameflu.